ly-379268 and Substance-Withdrawal-Syndrome

Drugs of abuse modify synaptic long-term potentiation and long-term depression (LTD) in the nucleus accumbens, and the impairment of synaptic plasticity in this brain region may be a universal feature of drug addiction. It is unknown whether metabotropic glutamate receptors (mGluRs) play a role in synaptic plasticity induced by drugs such as morphine. The neurochemical, electrophysiological, and Western blotting experiments reported here reveal a novel form of LTD in synapses of the shell region of the nucleus accumbens induced in vivo by low-frequency stimulation of the medial prefrontal cortex. This plasticity required the activation of N-methyl-d-aspartate receptors and mGluR2/3 but not mGluR5. The expression of mGluR2/3 was downregulated during withdrawal from repeated morphine exposure (10 days after the last injection), resulting in impaired low-frequency stimulation-induced LTD. These results indicate that withdrawal-induced mGluR2/3 downregulation alters neural plasticity after morphine exposure, which may be a mechanism contributing to drug addiction.

Topics: 2-Amino-5-phosphonovalerate; Amino Acids; Animals; Bridged Bicyclo Compounds, Heterocyclic; Down-Regulation; Electric Stimulation; Long-Term Synaptic Depression; Male; Microinjections; Morphine; Nucleus Accumbens; Prefrontal Cortex; Rats; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Receptors, N-Methyl-D-Aspartate; Substance Withdrawal Syndrome

Neuroadaptations in the nucleus accumbens (NAc) are associated with the development of drug addiction. Plasticity in synaptic strength and intrinsic excitability of NAc medium spiny neurons (MSNs) play critical roles in addiction induced by different classes of abused drugs. However, it is unknown whether morphine exposure influences synaptic strength, intrinsic excitability or both in NAc. Here we show that chronic withdrawal (10 days after the last injection) from repeated morphine exposure elicited potentiation in both glutamatergic synaptic strength and intrinsic excitability of MSNs in NAc shell (NAcSh). The potentiation of synaptic strength was demonstrated by an increase in the frequency of miniature excitatory postsynaptic currents (mEPSCs), a decrease in the paired-pulse ratio (PPR), and an increase in the ratio of α-amino-3-hydroxy-5-methyl-isoxazole propionic acid receptors (AMPAR)- to N-methyl-D-aspartate receptors (NMDAR)-mediated currents. The potentiation of intrinsic excitability was mediated by inhibition of the sustained potassium currents via extrasynaptic NMDAR activation. The function of the presynaptic group II metabotropic glutamate receptors (mGluR2/3) was downregulated, enhancing the probability of glutamate release on synaptic terminals during chronic morphine withdrawal. Pretreatment with the mGluR2/3 agonist LY379268 completely blocked potentiation of both synaptic strength and intrinsic excitability. These results suggest that chronic morphine withdrawal downregulates mGluR2/3 to induce potentiation of MSN glutamatergic synapse via increased glutamate release, leading to potentiation of intrinsic excitability. Such potentiation of both synaptic strength and intrinsic excitability might contribute to neuroadaptations induced by morphine application.

Topics: 2-Amino-5-phosphonovalerate; 6-Cyano-7-nitroquinoxaline-2,3-dione; Amino Acids; Analysis of Variance; Animals; Bridged Bicyclo Compounds, Heterocyclic; Disease Models, Animal; Down-Regulation; Electric Stimulation; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Excitatory Postsynaptic Potentials; In Vitro Techniques; Male; Morphine; Narcotics; Neurons; Neuroprotective Agents; Nucleus Accumbens; Patch-Clamp Techniques; Rats; Rats, Sprague-Dawley; Substance Withdrawal Syndrome; Synapses; Xanthines

Metabotropic glutamate 2/3 receptors (mGluR2/3) are emerging targets for the reduction of stress that contributes to drug relapse. The effect of a history of cocaine escalation on stress reactivity during abstinence and the role of mGlu2/3 receptors in stress in these animals were tested. Experiment 1-Rats trained to self-administer cocaine, under short (ShA, 1-h) or long (LgA, 6-h) access conditions, or noncaloric food pellets (Ctrl, 1-h), were tested for stress reactivity in the shock-probe defensive burying test following 1, 14, 42, or 84 days of abstinence. Experiment 2-Experimentally naive rats receiving the mGlu2/3 receptor agonist LY379268 (0, 0.3, 1.0, or 3.0 mg/kg) were tested in the defensive burying test to establish the anxiolytic efficacy of this compound in this model. Experiment 3-Rats with a history of ShA vs LgA cocaine self-administration, or a history of operant responding reinforced by noncaloric food pellets, were tested in the defensive burying test, following administration of LY379268 (0.3, 1.0, or 3.0 mg/kg) at 14 days of abstinence. LgA rats exhibited a two- to threefold increase in defensive burying at 1, 14, and 42 days of abstinence compared to ShA or control animals. LY379268 (3.0 mg/kg) reduced burying in all groups, whereas the 1.0-mg/kg dose reduced burying only in the LgA group. A robust and enduring increase in stress reactivity developed in rats with a history of daily 6-h access to cocaine. The anxiolytic-like effects of LY379268 identify mGlu2/3 receptors as targets for ameliorating stress-associated relapse risk, and point toward the possibility that a history of cocaine escalation in rats may modify glutamatergic function.

Topics: Amino Acids; Animals; Anti-Anxiety Agents; Bridged Bicyclo Compounds, Heterocyclic; Cocaine-Related Disorders; Dose-Response Relationship, Drug; Electroshock; Excitatory Amino Acid Agonists; Food; Male; Rats; Rats, Wistar; Receptors, Metabotropic Glutamate; Reinforcement, Psychology; Stress, Psychological; Substance Withdrawal Syndrome

Glutamate neurotransmission, and particularly metabotropic glutamate (mGlu) 2/3 receptors are implicated in behaviors of relevance to the addictive properties of nicotine. In laboratory animals, the mGlu2/3 receptor agonist LY379268 has been previously shown to decrease intravenous nicotine self-administration and cue-induced reinstatement of nicotine-seeking behavior. Such mGlu2/3 receptor agonists may therefore be useful medications to assist people in smoking cessation. Because of the demonstrated preclinical efficacy of mGlu2/3 receptor agonists in decreasing the primary rewarding and conditioned effects of nicotine in rats, we wished to examine whether such compounds could potentially influence additional aspects of nicotine dependence, such as nicotine withdrawal. We hypothesized that an mGlu2/3 receptor agonist would have negative effects on nicotine withdrawal because mGlu2/3 receptor antagonists have previously been shown to attenuate nicotine withdrawal-induced reward deficits, while an mGlu2/3 receptor agonist precipitated withdrawal-like reward deficits in rats dependent on nicotine. To test this hypothesis, we assessed the effects of the mGlu2/3 receptor agonist LY379268 on brain reward deficits associated with spontaneous nicotine withdrawal in rats. Brain reward function, as assessed by intracranial self-stimulation reward thresholds, was examined after removal of nicotine- or saline-delivering subcutaneous osmotic minipumps. LY379268 administration produced reward deficits in animals "withdrawing" from chronic saline administration and only tended to aggravate nicotine withdrawal-induced reward deficits in rats previously treated with nicotine. Thus, this mGlu2/3 agonist does not appear to significantly influence the affective depression-like aspects of nicotine withdrawal.

Topics: Amino Acids; Animals; Brain; Bridged Bicyclo Compounds, Heterocyclic; Male; Nicotine; Rats; Rats, Wistar; Receptors, Metabotropic Glutamate; Reward; Substance Withdrawal Syndrome